抗うつ薬の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

◆英語タイトル:Antidepressant Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
◆商品コード:MOR21MR066
◆発行会社(リサーチ会社):Mordor Intelligence
◆発行日:2021年2月
◆ページ数:112
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,250 ⇒換算¥488,750見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥546,250見積依頼/購入/質問フォーム
Corporate License(法人利用)USD7,500 ⇒換算¥862,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Mordor Intelligence社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、世界の抗うつ薬市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別(選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他)分析、うつ病別(大うつ病性障害、強迫性障害(OCD)、全般性不安障害(GAD)、パニック障害(PD)、その他)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の抗うつ薬市場規模:製品別(選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他)
・世界の抗うつ薬市場規模:うつ病別(大うつ病性障害、強迫性障害(OCD)、全般性不安障害(GAD)、パニック障害(PD)、その他)
・世界の抗うつ薬市場規模:地域別
・競争状況
・市場機会/将来の見通し
【レポートの概要】

The global antidepressant market is valued at approximately USD 14,538 million in 2020 and is expected to witness a revenue of USD 17,233 million in 2026, with a CAGR of 2.68% over the forecast period.

COVID-19 pandemic is expected to have a significant positive impact on the growth of the studied market. The pandemic is predicted to have a long and short term impact on the individual’s mental illness given the hurdles faced during the crisis, such as social isolation due to lockdown, job insecurity, and fear of being infected by Coronavirus. According to the survey conducted by Kaiser Family Foundation, Aug 2020, 64% of the household who had a healthcare worker reported having experienced at least one adverse effect, such as difficulty sleeping or eating, increase in alcohol consumption or substance use, and worsening chronic conditions, on their mental health and wellbeing during the COVID-19 pandemic. Additionally, the Coronoviris Aid, Relief and Economic Security Act (CARES) has provided USD 425 million for use by The Substance Abuse and Mental Health Services Administration for the expansion of mental health services to isolated veterans through telehealth and other related services. Thus, given the increasing incidence of depression and anxiety among the global population over the pandemic, the antidepressant market is expected to have a significant impact during the COVID-19 crisis.

Moroever, the market is majorly driven by the rising cases of depression, increasing awareness about depression, and the emergence of novel biologics. According to the Centers for Disease Control and Prevention (CDC) WISQARS leading Cause of Death Reports, 2018, Suicide was the tenth leading cause of all deaths in the United States, claiming the lives of over 48,000 people in 2018. Similarly, as per the National Survey on Drug Use and Health (NSDUH), 2019, the prevalence of serious suicidal thoughts was highest among young adults aged 18-25. Depression mainly occurs due to the factors, such as social isolation and stressful work environment, which contributed the most to increasing the number of people suffering from depression. The number of people falling prey to depression and related disorders is expected to continue to increase, as a result of improper eating habits, stressful work schedule, increasing isolation from family and loved ones due to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward. Additionally, in countries, such as the United Kingdom and the United States, which are characterized by their fast-paced economies, the percentage of the affected population in every age group is quite high. According to the Anxiety and Depression Foundation facts and statistics, Generalized Anxiety Disorder affects 6.8 million adults or 3.1% of the United States population per year. Thus, the rising cases of depression across the world are expected to drive the overall growth of the market studied over the forecast period.

However, the availability of non-drug treatments and side effects associated with the anti-depressants is projected to hinder the market growth over the forecast period.

Key Market Trends

Major Depressive Disorder Segment by Depressive Disorder is Projected to Account for the Significant Share Over the Forecast Period

The major depressive disorder possible causes comprise of the combination of biological, psychological, and social sources of distress. The major risk factors include family history, significant life changes, certain medications, chronic health problems, and substance abuse. As per the data published by the National Institute of Mental Health, In 2017, an estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all US adults and is majorly prevalent in women as compared to men. According to the research article published in the Brazilian Journal of Psychiatry, 2020, the lifetime prevalence of major depressive disorder was estimated to range from 2% in China, 6.7% in South Korea, 20.5% in Chile, to 21% in France and the in European countries the average lifetime prevalence was 11.32%, while average 12-month prevalence was 5.2%. Thus, the high prevalence of major depressive disorder globally is expected to surge the demand for antidepressants over the forecast period.

Most commonly, selective serotonin reuptake inhibitors (SSRI) are used in the treatment of major depression, while there are some therapies available to normalize brain changes associated with depression. Thus, owing to the rising patient pool and recent product launches, the market is expected to witness high growth over the forecast period.

North America is has been Dominant and is Projected to Have Significant Share in the Global Market Over The Forecast Period

The increasing cases of depression are one of the major factors that are expected to drive the overall growth of the antidepressant market in North America, particularly in the United States over the forecast period. Moreover, there is a rise in the geriatric population in the United States, which is expected to create more opportunities for market players in the region. According to the Anxiety and Depression Association of America, Facts, and Statistics, anxiety disorders is one of the most common mental illness in the United States, affecting approximately 40 million American adults every year, which is 18.1% of the total population of the United States. Additionally, more than 16.1 million American adults suffer from Major Depressive disorder every year and are more prevalent in women than men. Thus, the increasing prevalence of disorders and increasing rate of consumption of antidepressants are expected to drive the market studied during the forecast period.

The prevalence of depression has increased during the COVOD-19 pandemic in the United States. According to the research article published in JAMA Network Open, 2020, prevalence of depression symptoms was more than 3-times higher during COVID-19 compared with before the COVID-19 pandemic in United States. This was majorly attributed to the increased exposure to stress due to job loss and social isolation. Hence, given the aforementioned factors, COVID-19 is expected to boost the antidepressant market during the Pandemic in United States.

Additionally, the growing FDA approvals and increasing pipeline products by key players concentrated in the region drive the studied market. For instance, in March 2019, US FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of resistant depression in adults. Thus, in view of the aforementioned factors, the antidepressant market is expected to witness significant growth over the forecast period in North America,

Competitive Landscape

The market studied comprises a combination of multinational and domestic players. The entry barriers are comparatively less, and most of the drugs are available over the counter. The companies are actively involved in the global expansion of their product portfolio through partnerships, collaborations, and acquisitions. Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc. Additionally, the research and development activities by the key players have resulted in increasing product approvals and have a pipeline of products under development.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

【レポートの目次】

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cases of Depression around the World
4.2.2 Increasing Awareness about Depression
4.2.3 Emergence of Novel Biologics
4.3 Market Restraints
4.3.1 Preference of Non-pharmacological Therapies over Pharmacological Therapies
4.3.2 Side-effects and Patent Expiry of Antidepressant Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Selective Serotonin Reuptake Inhibitor (SSRI)
5.1.2 Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
5.1.3 Tricyclic Antidepressant (TCA)
5.1.4 Monoamine Oxidase Inhibitor (MAOI)
5.1.5 Other Products
5.2 By Depressive Disorder
5.2.1 Major Depressive Disorder
5.2.2 Obsessive-compulsive Disorder (OCD)
5.2.3 Generalized Anxiety Disorder (GAD)
5.2.4 Panic Disorder (PD)
5.2.5 Other Depressive Disorders
5.3 Geography
5.3.1 North America
5.3.1.1 United States (By Product, and By Depressive Disorder)
5.3.1.2 Canada (By Product, and By Depressive Disorder)
5.3.1.3 Mexico (By Product, and By Depressive Disorder)
5.3.2 Europe
5.3.2.1 Germany (By Product, and By Depressive Disorder)
5.3.2.2 United Kingdom (By Product, and By Depressive Disorder)
5.3.2.3 France (By Product, and By Depressive Disorder)
5.3.2.4 Italy (By Product, and By Depressive Disorder)
5.3.2.5 Spain (By Product, and By Depressive Disorder)
5.3.2.6 Rest of Europe (By Product, and By Depressive Disorder)
5.3.3 Asia-Pacific
5.3.3.1 China (By Product, and By Depressive Disorder)
5.3.3.2 Japan (By Product, and By Depressive Disorder)
5.3.3.3 India (By Product, and By Depressive Disorder)
5.3.3.4 Australia (By Product, and By Depressive Disorder)
5.3.3.5 South Korea (By Product, and By Depressive Disorder)
5.3.3.6 Rest of Asia-Pacific (By Product, and By Depressive Disorder)
5.3.4 Middle East and Africa
5.3.4.1 GCC (By Product, and By Depressive Disorder)
5.3.4.2 South Africa (By Product, and By Depressive Disorder)
5.3.4.3 Rest of Middle East and Africa (By Product, and By Depressive Disorder)
5.3.5 South America
5.3.5.1 Brazil (By Product, and By Depressive Disorder)
5.3.5.2 Argentina (By Product, and By Depressive Disorder)
5.3.5.3 Rest of South America (By Product, and By Depressive Disorder)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbiVe, Inc (Allergan PLC)
6.1.2 AstraZeneca
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 H. Lundbeck AS
6.1.7 Merck & Co. Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Sun Pharmaceuticals Pvt Ltd
6.1.11 Koninklijke Philips N.V.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗うつ薬の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆